Checkpoint NOW Afreen Shariff

Learn from the experts about the costs associated with irAEs in patients treated for Renal Cell Carcinoma. Join our hosts Dr. Afreen Shariff and Dr. Tian Zhang as they discuss with guest experts- medical Oncologists Dr. Daniel Geynisman and Dr. Bradley McGregor, MD for an informative and high yield discussion regarding real and hidden costs of adverse events and how this impacts patients. 

Join host Dr. Afreen Shariff and Dr. Tian Zhang as they discuss with guest expert and Psychologist, Dr. Rebecca Shelby about the emotional impacts like stress, depression, and anxiety associated with side effects from cancer treatments.

Join our hosts Dr. Afreen Shariff and Dr. Tian Zhang as they discuss with guest experts from Dana Farber Cancer Institute, GU Oncologist Dr. Toni Choueiri and Quantitative Geneticist Dr. Sasha Gusev as they discuss Germline variants associated with immune checkpoint blockade and associated irAEs.

Hosts: Join our hosts Dr. Afreen Shariff and Dr. Tian Zhang as they discuss with guest experts and thyroidologists Dr. Trevor Angell and Dr. Anupam Kotwal as they discuss information regarding thyroid disease in cancer patients for patients and caregivers.

Join our hosts Dr. Afreen Shariff and Dr. Tian Zhang as they discuss with Dena Battle from KCCure- an evidence based, patient driven advocacy organization. Dena shares her deep insight on patient, caregiver experiences around toxicity management and how we can learn from each other to improve patient outcomes.

Join our hosts Dr. Afreen Shariff and Dr. Tian Zhang as they talk to expert oncologists Dr. Sharon and Dr. Nagash to learn about Immune Checkpoint Inhibitors in special populations.
Dr. Sharon is an accomplished Oncologist at the National Cancer Institute. He co-Directs immunotherapy trials at the Cancer Therapy Evaluation Program (also known as CTEP) and serves as an attending physician in NCI's Developmental Therapeutics Clinic. As part of his work in immunotherapy drug development, he has made a major effort to advance the understanding of immune-related adverse events, including the establishment of the Alliance-NIH irAE Biorepository.
Dr. Naqash, is an Oncologist with a focus on Early phase clinical trials, drug development and biomarkers in Immunotherapy. He is currently an Assistant professor of Medicine at the Oklahoma Health Stephenson Cancer Center.